Curran Terrie — SEC insider filings
SEC reporting owner CIK 1690298. 34 insider filings on record with FilingPulse; latest filed 2026-08-28.
Transaction summary — filings shown
Covers all 34 filings on record, filed 2020-09-17 to 2026-08-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 33,419 shares, $252,861 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 15 legs across 12 filings — 191,421 shares, $3,665,641 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 50.
- Largest priced transaction: sale of 37,135 shares @ $25.03 ($929,489) in Myovant Sciences Ltd., filed 2021-09-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. (PHAT) | President and Chief Executive, Director | 18 | 2 legs · 33,419 sh · $252,861 | 8 legs · 90,104 sh · $1,249,490 | 15 |
| Myovant Sciences Ltd. (MYOV) | Director | 6 | — | 3 legs · 53,358 sh · $1,337,877 | 17 |
| Arcutis Biotherapeutics, Inc. (ARQT) | Director | 10 | — | 4 legs · 47,959 sh · $1,078,274 | 18 |
Insider filings — Curran Terrie
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-28 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 11,148 @ $7.51 · Sale (S): 11,148 @ $25.03 · Option exercise (M): 27,052 @ $8.63 · Sale (S): 27,052 @ $25.03 · Option exercise (M): 11,148 (derivative) @ $0 · Option exercise (M): 27,052 (derivative) @ $0 | EDGAR |
| 2026-08-24 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Option exercise (M): 1,072 @ $7.51 · Sale (S): 1,072 @ $26.04 · Option exercise (M): 1,072 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 5,778 @ $0 · Grant/award (A): 16,667 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 7,609 @ $0 · Grant/award (A): 20,568 (derivative) @ $0 | EDGAR |
| 2025-03-03 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Grant/award (A): 342,500 (derivative) @ $0 | EDGAR |
| 2025-01-23 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Sale (S): 19,109 @ $6.59 | EDGAR |
| 2024-11-13 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Sale (S): 8,687 @ $10.85 | EDGAR |
| 2024-07-17 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Sale (S): 33,848 @ $11.72 | EDGAR |
| 2024-06-18 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 10,139 @ $0 · Grant/award (A): 27,052 (derivative) @ $0 | EDGAR |
| 2024-03-26 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Sale (S): 16,851 @ $9.11 | EDGAR |
| 2024-01-22 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Grant/award (A): 475,000 (derivative) @ $0 | EDGAR |
| 2023-11-03 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Grant/award (A): 37,500 @ $0 | EDGAR |
| 2023-07-17 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Grant/award (A): 200,000 · Disposition to issuer (D): 175,000 (derivative) · Disposition to issuer (D): 225,000 (derivative) | EDGAR |
| 2023-06-02 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 4,375 @ $0 · Grant/award (A): 12,220 (derivative) @ $0 | EDGAR |
| 2023-04-07 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Purchase (P): 12,919 @ $7.82 | EDGAR |
| 2023-03-10 | 4 | Myovant Sciences Ltd. (MYOV) | Disposition to issuer (D): 3,673 · Disposition to issuer (D): 33,846 (derivative) · Disposition to issuer (D): 11,154 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 5,250 (derivative) · +2 more | EDGAR |
| 2023-03-03 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Sale (S): 1,436 @ $8.54 | EDGAR |
| 2023-01-20 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Grant/award (A): 97,500 @ $0 · Sale (S): 5,821 @ $8.20 · Grant/award (A): 162,500 (derivative) @ $0 | EDGAR |
| 2022-11-23 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Sale (S): 1,526 @ $9.60 | EDGAR |
| 2022-10-28 | 4 | Myovant Sciences Ltd. (MYOV) | Grant/award (A): 9,859 @ $0 | EDGAR |
| 2022-09-02 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Grant/award (A): 7,500 @ $0 | EDGAR |
| 2022-06-03 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 4,312 @ $0 · Grant/award (A): 11,796 (derivative) @ $0 | EDGAR |
| 2022-05-20 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Grant/award (A): 12,000 @ $0 | EDGAR |
| 2022-05-16 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Purchase (P): 20,500 @ $7.41 | EDGAR |
| 2022-03-11 | 4/A | Phathom Pharmaceuticals, Inc. (PHAT) | Holdings only — no transactions reported | EDGAR |
| 2022-01-21 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Grant/award (A): 41,250 @ $0 · Grant/award (A): 206,250 (derivative) @ $0 | EDGAR |
| 2021-11-09 | 4 | Myovant Sciences Ltd. (MYOV) | Grant/award (A): 21,096 (derivative) @ $0 | EDGAR |
| 2021-09-13 | 4 | Myovant Sciences Ltd. (MYOV) | Option exercise (M): 4,850 @ $7.65 · Sale (S): 4,850 @ $25.58 · Option exercise (M): 4,850 (derivative) @ $0 | EDGAR |
| 2021-09-03 | 4 | Myovant Sciences Ltd. (MYOV) | Option exercise (M): 11,373 @ $7.65 · Sale (S): 11,373 @ $25 · Option exercise (M): 37,135 @ $7.65 · Sale (S): 37,135 @ $25.03 · Option exercise (M): 11,373 (derivative) @ $0 · Option exercise (M): 37,135 (derivative) @ $0 | EDGAR |
| 2021-06-11 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 13,391 (derivative) @ $0 | EDGAR |
| 2021-03-23 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Option exercise (M): 11,513 @ $6.95 · Sale (S): 10,373 @ $43.24 · Sale (S): 1,140 @ $44.08 · Option exercise (M): 11,513 (derivative) @ $0 | EDGAR |
| 2021-01-29 | 4 | Phathom Pharmaceuticals, Inc. (PHAT) | Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2020-11-04 | 4 | Arcutis Biotherapeutics, Inc. (ARQT) | Grant/award (A): 37,500 (derivative) @ $0 | EDGAR |
| 2020-09-17 | 4 | Myovant Sciences Ltd. (MYOV) | Grant/award (A): 21,603 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1690298 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs